Evidence map›Paper›PMID 36466927›Full record

ArticleFrontiers in immunology2022

Neutralizing epitopes on

Baohua Chen, Kay Perry, Rongsheng Jin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Baohua ChenDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, United States.
Kay PerryNE-CAT, Advanced Photon Source, Argonne National Laboratory, Argonne, IL, United States.
Rongsheng JinDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, United States.
University of California, Irvine · USArgonne National Laboratory · US

Funding

User Training and OutreachP30GM124165 · NIGMS · CORNELL UNIVERSITY · PI Nozomi Ando, J Christopher Fromme · 2018 to 2026
$34.2M
Structure and Function of C. Difficile ToxinsR01AI139087 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI Min Dong, Rongsheng Jin · 2018 to 2026
$7.4M
Developing broad-spectrum therapeutics against C. difficile toxinsR01AI158503 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI JIN, RONGSHENG · 2021 to 2025
$3.9M
Structural basis of Rho glucosylation by Clostridium difficile toxinsR21AI156092 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI JIN, RONGSHENG · 2021 to 2022
$432k
NIAID NIH HHS R01 AI139087NIAID NIH HHS R01 AI158503NIAID NIH HHS R21 AI156092NIGMS NIH HHS P30 GM124165
6 · The paper itself

Abstract

Toxin A (TcdA) and toxin B (TcdB) are two key virulence factors secreted by

Indexed as

Bacterial ToxinsClostridioides difficileSingle-Domain AntibodiesAnimalsBoron CompoundsEpitopesBacterial ToxinsBoron CompoundsEpitopesSingle-Domain AntibodiestrimethylaminocarboxyldihydroboranantibodyantitoxinC. difficile infectionClostridioides difficilelarge clostridial glucosylating toxinTcdATcdBVHH

Identifiers

PMID36466927
PMCPMC9709291
OpenAlexW4309153392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.